Lineage Cell Therapeutics (LCTX) Change in Receivables (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Change in Receivables of -$154000.0 for Q1 2026, up 63.68% year-over-year from -$94086.5 in Q1 2025, and down 118.62% quarter-over-quarter from $827000.0 in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Change in Receivables (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$154000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 63.68% year-over-year to -$154000.0; the TTM figure through Mar 2026 stood at $586000.0 (up 324.64% YoY), while the FY2025 annual figure was $316000.0, up 398.11% from the prior year.
- Change in Receivables for Q1 2026 stood at -$154000.0, down from $827000.0 in the prior quarter.
- The five-year high for Change in Receivables was $827000.0 in Q4 2025, with the low at -$50.3 million in Q1 2022.
- The 5-year median for Change in Receivables is -$6000.0 (2023), against an average of -$2.9 million.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables sank 37374.81% in 2022, then jumped 2916.67% in 2024.
- Lineage Cell Therapeutics' Change in Receivables stood at -$108000.0 in 2022, then jumped by 382.41% to $305000.0 in 2023, then slipped by 23.61% to $233000.0 in 2024, then soared by 254.94% to $827000.0 in 2025, then sank by 118.62% to -$154000.0 in 2026.
- Business Quant data shows LCTX's Change in Receivables at -$154000.0 in Q1 2026, $827000.0 in Q4 2025, and -$130000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | -19,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19,000.00 |
| Mar 31, 2026 | -154,000.00 |
| Dec 31, 2025 | 827,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Mar 31, 2025 | -424,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Mar 31, 2024 | -668,000.00 |
| Dec 31, 2023 | 305,000.00 |
| Sep 30, 2023 | -6,000.00 |
| Jun 30, 2023 | 242,000.00 |
| Mar 31, 2023 | -95,000.00 |
| Dec 31, 2022 | -108,000.00 |
| Sep 30, 2022 | -95,000.00 |
| Jun 30, 2022 | 210,000.00 |
| Mar 31, 2022 | -50.32 Mn |
| Dec 31, 2021 | 753,000.00 |
| Sep 30, 2021 | -249,000.00 |